Urodynamix Technologies Ltd.
TSX VENTURE : URO

Urodynamix Technologies Ltd.

April 28, 2009 09:00 ET

Urodynamix Receives Financial Contribution From NRC-IRAP to Support Development of NIRS Technology to Improve the Minimally Invasive Treatment (MIT) of Benign Prostatic Hypertrophy (BPH)

VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 28, 2009) - Urodynamix Technologies Ltd. (TSX VENTURE:URO) has received approval for a non-refundable financial contribution of up to $322,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP). This funding assistance will help accelerate the development and commercialization of its new URO NIRS technology. This technology is expected to significantly improve the efficacy of the minimally invasive treatment (MIT) of benign prostatic hypertrophy (BPH) and in turn lead to growth in the number of MIT procedures.

MIT is used for the treatment of lower urinary tract symptoms (LUTS) due to BPH in men. Transurethral microwave thermotherapy treatment (TUMT) and other clinically available MIT procedures including transurethral needle ablation (TUNA) and transrectal high intensity focused ultrasound (HIFU) are to intended to provide a one-time efficacious treatment of LUTS due to BPH as minimally invasive alternatives to pharmacotherapy, transurethral resection of the prostate (TURP), photoselective vaporization of the prostate (PVP), open prostatic enucleation, or other surgical therapies.

Urodynamix's new technology applies near infrared spectroscopy (NIRS) to help physicians improve the safety and effectiveness of the MIT treatment for enlarged prostates. URO NIRS works by monitoring the progression of the coagulative necrosis in the prostate during the MIT treatment to indicate when sufficient thermal energy has been delivered to destroy partial enlarged prostate tissue by way of necrosis. URO NIRS will allow physicians to optimize treatment for each patient despite individual variations in prostate blood flow or vascularity for best outcome of the treatment. Management believes that by using URO NIRS, efficacy of the MIT treatment will be significantly improved and a reduced rate of retreatment due to under-treatment of TUMT will attract more physicians and patients to use MIT procedures over the invasive treatments.

Along with technology and business advisory services, NRC-IRAP will contribute up to $322,000 over the next 12 months to support the development of NIRS technology. This technology will be used to improve the efficacy of the MIT procedures including transurethral microwave thermotherapy treatment or TUMT.

"This financial support from the Government of Canada through the NRC-IRAP program will allow us to develop this next generation product more quickly. It will also address a large market opportunity for improved MIT procedures using our NIRS technology platform," says Barry Allen, President and CEO of Urodynamix.

BPH is one of the most common diseases in aging men. An estimated one third of men older than 50 years develop LUTS, and 30% of these men eventually require surgery. Irritative voiding symptoms, such as frequency, urgency, urge incontinence, and nocturia, severely affect patients' quality of life and perception of health. If left untreated, bladder outlet obstruction can lead to urinary stasis, predisposing patients to urinary tract infections and urosepsis, bladder dysfunction, bladder calculi, and renal failure. Adenomatous prostatic growth is believed to begin at approximately age 30 years. An estimated 50% of men have histologic evidence of BPH by age 50 years and 75% by age 80 years. In 40-50% of these patients, BPH becomes clinically significant.

About Urodynamix Technologies Ltd.

Urodynamix Technologies is a Canadian medical device company developing and commercializing non-invasive medical technology based on proprietary applications of near-infrared spectroscopy (NIRS). The Company is currently focused on products that aid in the diagnosis and treatment of urinary incontinence, lower urinary tract symptoms, prostate cancer, benign prostatic hyperplasia, and traumatic increases in intra-abdominal pressure that cause abdominal compartment syndrome. Urodynamix's breakthrough medical technology has the potential to beneficially affect more than 200 million people worldwide.

Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information